175 related articles for article (PubMed ID: 37424871)
21. Longitudinal Analysis of the Effect of Radioiodine Therapy on Ovarian Reserve in Females with Differentiated Thyroid Cancer.
van Velsen EFS; Visser WE; van den Berg SAA; Kam BLR; van Ginhoven TM; Massolt ET; Peeters RP
Thyroid; 2020 Apr; 30(4):580-587. PubMed ID: 31928168
[No Abstract] [Full Text] [Related]
22. Radioactive iodine therapy for pediatric Graves' disease: a single-center experience over a 10-year period.
Kaplowitz PB; Jiang J; Vaidyanathan P
J Pediatr Endocrinol Metab; 2020 Mar; 33(3):383-389. PubMed ID: 31603857
[TBL] [Abstract][Full Text] [Related]
23. Effects of Thyroid Hormone Withdrawal and Recombinant Human Thyrotropin on Glomerular Filtration Rate During Radioiodine Therapy for Well-Differentiated Thyroid Cancer.
Coura-Filho GB; Willegaignon J; Buchpiguel CA; Sapienza MT
Thyroid; 2015 Dec; 25(12):1291-6. PubMed ID: 26446582
[TBL] [Abstract][Full Text] [Related]
24. Proprotein convertase subtilisin/kexin type 9 (PCSK9), soluble lectin-like oxidized LDL receptor 1 (sLOX-1) and ankle brachial index in patients with differentiated thyroid cancer.
Ozkan C; Akturk M; Altinova AE; Cerit ET; Gulbahar O; Yalcin MM; Cakir N; Balos Toruner F
Endocr J; 2015; 62(12):1091-9. PubMed ID: 26490048
[TBL] [Abstract][Full Text] [Related]
25. Effects of thyroid hormone withdrawal on natriuretic peptides during radioactive iodine therapy in female patients with differentiated thyroid cancer.
Stanciu AE; Hurduc AE; Stanciu MM
Scand J Clin Lab Invest; 2016 Dec; 76(8):626-631. PubMed ID: 27666870
[TBL] [Abstract][Full Text] [Related]
26. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.
Iizuka Y; Katagiri T; Ogura K; Mizowaki T
Ann Nucl Med; 2019 Jul; 33(7):495-501. PubMed ID: 30955202
[TBL] [Abstract][Full Text] [Related]
27. Recombinant or endogenous thyroid-stimulating hormone for radioactive iodine therapy in thyroid cancer: state of knowledge and current controversies.
Coerts HI; de Keizer B; Marlowe RJ; Verburg FA
Eur J Endocrinol; 2023 Feb; 188(2):. PubMed ID: 36655579
[TBL] [Abstract][Full Text] [Related]
28. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
[TBL] [Abstract][Full Text] [Related]
29. Factors related to clinical hypothyroid severity in thyroid cancer patients after thyroid hormone withdrawal.
Huang SC; Wu VC; Lin SY; Sheu WH; Song YM; Lin YH; Wu CC; Chang WD
Thyroid; 2009 Jan; 19(1):13-20. PubMed ID: 19072673
[TBL] [Abstract][Full Text] [Related]
30. Effects of thyroid hormone withdrawal on metabolic and cardiovascular parameters during radioactive iodine therapy in differentiated thyroid cancer.
An JH; Song KH; Kim DL; Kim SK
J Int Med Res; 2017 Feb; 45(1):38-50. PubMed ID: 27856930
[TBL] [Abstract][Full Text] [Related]
31. Correlation of thyroid hormone measurements with thyroid stimulating hormone stimulation test results in radioiodine-treated cats.
Wakeling J; Hall T; Williams TL
J Vet Intern Med; 2020 Nov; 34(6):2265-2275. PubMed ID: 33044029
[TBL] [Abstract][Full Text] [Related]
32. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients.
Pötzi C; Moameni A; Karanikas G; Preitfellner J; Becherer A; Pirich C; Dudczak R
Clin Endocrinol (Oxf); 2006 Oct; 65(4):519-23. PubMed ID: 16984246
[TBL] [Abstract][Full Text] [Related]
33. Health-related quality-of-life study in patients with carcinoma of the thyroid after thyroxine withdrawal for whole body scanning.
Chow SM; Au KH; Choy TS; Lee SH; Yeung NY; Leung A; Leung A; Leung HL; Shek CC; Law SC
Laryngoscope; 2006 Nov; 116(11):2060-6. PubMed ID: 17075410
[TBL] [Abstract][Full Text] [Related]
34. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
[TBL] [Abstract][Full Text] [Related]
35. Effects of Short-Term Hypothyroidism on the Lipid Transfer to High-Density Lipoprotein and Other Parameters Related to Lipoprotein Metabolism in Patients Submitted to Thyroidectomy for Thyroid Cancer.
Sigal GA; Tavoni TM; Silva BMO; Kalil Filho R; Brandão LG; Maranhão RC
Thyroid; 2019 Jan; 29(1):53-58. PubMed ID: 30412041
[TBL] [Abstract][Full Text] [Related]
36. Discriminant function analysis of the occurrence risk of abnormal electrocardiogram in thyroidectomized differentiated thyroid carcinoma patients with short-term overt hypothyroidism.
Guan F; Zhao H; Jiao B; Liu S; Sa R; Hou S; Lin Q; Wang Q; Lin C
Ann Nucl Med; 2016 Feb; 30(2):138-44. PubMed ID: 26692011
[TBL] [Abstract][Full Text] [Related]
37. Effects of thyroxine withdrawal in biochemical parameters and cardiac function and structure in patients with differentiated thyroid cancer.
Chrisoulidou A; Pazaitou-Panayiotou K; Kaprara A; Platoyiannis D; Lafaras C; Boudina M; Georgiou E; Drimonitis A; Bischiniotis T; Vainas I
Minerva Endocrinol; 2006 Jun; 31(2):173-8. PubMed ID: 16682940
[TBL] [Abstract][Full Text] [Related]
38. Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma.
Golger A; Fridman TR; Eski S; Witterick IJ; Freeman JL; Walfish PG
J Endocrinol Invest; 2003 Oct; 26(10):1023-31. PubMed ID: 14759077
[TBL] [Abstract][Full Text] [Related]
39. Comparison of conventional L-thyroxine withdrawal and moderate hypothyroidism in preparation for whole-body 131-I scan and thyroglobulin testing.
Marturano I; Russo M; Spadaro A; Latina A; Malandrino P; Regalbuto C
J Endocrinol Invest; 2015 Sep; 38(9):1017-22. PubMed ID: 26070652
[TBL] [Abstract][Full Text] [Related]
40. Comparison of thyroid hormone withdrawal and recombinant human thyroid-stimulating hormone administration for adjuvant therapy in patients with intermediate- to high-risk differentiated thyroid cancer.
Iizuka Y; Katagiri T; Ogura K; Inoue M; Nakamura K; Mizowaki T
Ann Nucl Med; 2020 Oct; 34(10):736-741. PubMed ID: 32643022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
